Delivery Order SPE2DB22D2009-SPE2DB25FL9FT

Award Date 5/15/25
Potential Completion Date 5/16/25
Potential Value $1.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of Dextroamp-Amphet ER 20 mg capsules, a prescription medication. The fixed-price contract has a ceiling value of $3,168.96 and a performance period ending on May 2, 2025. It is not a set-aside contract, indicating open competition. Amerisourcebergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with DLA...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the leading pharmaceutical distributor Amerisourcebergen Corporation. The $1,237.14 award is for the supply of 4,564,232,196 units of the drug Dextroamp-Amphet ER 25 mg capsules. This delivery order falls under an indefinite delivery contract (IDC) held by Amerisourcebergen Drug Corp, valued at up to $999,999,999.00 through December 2025, which serves as the...
This federal contract award is for the delivery of 4,563,678,035 units of the pharmaceutical product Dextroamp-Amphet ER 25 mg capsules to the Defense Logistics Agency (DLA). The award, with a ceiling value of $1,320.00, was made to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is a Firm Fixed Price Delivery Order with a completion date of February 16, 2024. Amerisourcebergen Drug Corp, a major pharmaceutical distributor, holds a significant...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,111.63, is for the delivery of 4567360072 - DEXTROAMP-AMPHET ER 20 MG CAP 100S. The contract is a firm fixed price delivery order, with a performance period through February 25, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company and subsidiary of Cencora, Inc. The contract is for the delivery of 4,561,904,774 units of Dextroamphet-amphet ER 20 mg capsules in 100-count bottles. The total ceiling value of the contract is $1,936.07, with a firm fixed price. The contract has an ultimate completion date of August 22, 2023. This contract is not designated with a set-aside...
This federal contract award, valued at $1,044.01, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of 4,568,028,081 units of the medication Dextroamp-Amphet ER 20 mg capsules. The contract is a Firm Fixed Price Delivery Order with an ultimate completion date of April 24, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,916.02, is for the delivery of 4567873454 - DEXTROAMP-AMPHET ER 30 MG CAP 100S, a pharmaceutical product. The contract is a firm fixed-price, non-set-aside award with an ultimate completion date of April 11, 2025. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite...
This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $1,532.64 and is for the delivery of 4,568,107,645 units of the prescription medication Dextroamphetamine ER 10 mg capsules. The contract is a firm fixed-price, non-set-aside award with a period of performance through May 2, 2025. Amerisourcebergen Drug Corp holds a...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,563,518,973 units of the pharmaceutical drug Dextroamp-Amphet ER 10 mg capsules. The contract has a completion date of February 2, 2024 and a potential value of $2,074.48. This delivery order contract is part of a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00 awarded to...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,576.41, is for the delivery of DEXTRO-AMP ER 5MG 100S, a prescription medication. The contract has an ultimate completion date of May 1, 2025 and is not set aside for any special type of business. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC)...
  • SPE2DB22D2009
    Indefinite Delivery Contract
  • SPE2DB22D2009-SPE2DB25FL9FT
    Delivery Order

This is a firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of the drug Dextroamp-Amphet ER 20 mg capsules, with a ceiling value of $1,436.69 and a performance period through May 16, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00, which provides a comprehensive global pharmaceutical support vehicle with a performance period through December 2026. This delivery order contract is not designated as a set-aside.

Generated 8/14/25, 9:50 AM